|
|
Volumn 65, Issue 6, 2016, Pages 765-767
|
|
A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA2B INTERFERON;
B RAF KINASE;
C PEPTIDE;
DABRAFENIB;
GLUCOSE;
GLUTAMATE DECARBOXYLASE ANTIBODY;
HEMOGLOBIN A1C;
INTERLEUKIN 2;
IPILIMUMAB;
LONG ACTING INSULIN;
PEMBROLIZUMAB;
SHORT ACTING INSULIN;
TRAMETINIB;
VEMURAFENIB;
ANTINEOPLASTIC AGENT;
INSULIN DERIVATIVE;
MONOCLONAL ANTIBODY;
PROGRAMMED DEATH 1 RECEPTOR;
ADULT;
AXILLARY LYMPH NODE;
BODY WEIGHT DISORDER;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER STAGING;
CANCER SURGERY;
CASE REPORT;
COMPASSIONATE USE;
CUTANEOUS MELANOMA;
DRUG MEGADOSE;
DRUG WITHDRAWAL;
FATIGUE;
GASTROESOPHAGEAL REFLUX;
GENE MUTATION;
GLUCOSE BLOOD LEVEL;
HAIR DISCOLORATION;
HUMAN;
HYPOTHYROIDISM;
IMMUNOTOXICITY;
INSULIN DEPENDENT DIABETES MELLITUS;
LETTER;
LIVER TUMOR;
LUNG BIOPSY;
LYMPH NODE DISSECTION;
LYMPHADENOPATHY;
MALE;
METASTATIC MELANOMA;
MIDDLE AGED;
POLYDIPSIA;
POLYURIA;
PRIORITY JOURNAL;
RASH;
TUMOR BIOPSY;
WEIGHT GAIN;
WEIGHT REDUCTION;
WIDE EXCISION;
ADVERSE EFFECTS;
ANTAGONISTS AND INHIBITORS;
COMPLICATION;
DIABETES MELLITUS, TYPE 1;
DISEASE MANAGEMENT;
MELANOMA;
MOLECULARLY TARGETED THERAPY;
OUTCOME ASSESSMENT;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
DIABETES MELLITUS, TYPE 1;
DISEASE MANAGEMENT;
HUMANS;
INSULINS;
MALE;
MELANOMA;
MIDDLE AGED;
MOLECULAR TARGETED THERAPY;
PATIENT OUTCOME ASSESSMENT;
PROGRAMMED CELL DEATH 1 RECEPTOR;
TREATMENT OUTCOME;
|
|
EID: 84962798338
PISSN: 03407004
EISSN: 14320851
Source Type: Journal
DOI: 10.1007/s00262-016-1835-4 Document Type: Letter |
|
Times cited : (69)
|
|
References (5)
|
